• English (United States)

You are leaving the website

You are now leaving Xalutestudy.com and going to a trusted partner website.

Go back to Xalutestudy.com Leave this website
Xalute Logo Xalute Logo
  • About the Study
  • FAQs
  • Patient Resources
  • Site Resources
  • See if you qualify

Mechanism of Action for Xaluritamig

Xaluritamig is a novel T-cell engager immunotherapy being developed for advanced prostate cancer. Xaluritamig is designed to activate the immune system against prostate cancer cells by creating an immune synapse between immune T cells and STEAP1, a protein that is uniquely overexpressed in prostate cancer cells.1-3



Watch this video to learn more about the mechanism of action of Xaluritamig.

1. Kelly WK, Danila DC, Lin CC, et al. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14(1):76-89. doi: 10.1158/2159-8290

2. Nolan-Stevaux O, Li C, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290

3. Xu M, Evans L, Bizzaro CL, et al. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel). 2022;14(16):4034. doi: 10.3390/cancers14164034

/Reusable Clone Sites/Patient Site/Standard O-US Site/Home/Download Page1/Resource1

You are leaving the website

You are now leaving Xalutestudy.com and going to a trusted partner website.

Go back to Xalutestudy.com Leave this website
Back to Top
Amgen Logo Amgen Logo
Contact Us Terms of Use Privacy Statements Cookie Settings Consumer Health Data Privacy Policy

© 2025 Amgen Inc. All rights reserved. | This site is intended for US residents only.